文献速递心境障碍精神分裂症与精神病性障碍物质与行为成瘾

精神障碍对躯体疾病临床结局的影响:评估人群归因分数和广义影响分数的伞状综述

Impact of mental disorders on clinical outcomes of physical diseases: an umbrella review assessing population attributable fraction and generalized impact fraction.
PubMed 文献 · World Psychiatry · 2023-01-01

仅抑郁障碍与心力衰竭患者全因死亡率、精神分裂症与心血管疾病患者心血管死亡率两项关联达I级证据;抑郁障碍、酒精使用障碍和精神分裂症在多种躯体疾病中显示可预防的额外风险。

要点

  • 抑郁障碍与心力衰竭患者全因死亡率关联达I级证据(HR=1.44)。
  • 精神分裂症与心血管疾病患者心血管死亡率关联达I级证据(RR=1.54)。
  • 酒精使用障碍与丙肝患者失代偿性肝硬化人群归因分数最高(30.56%)。

核心结论

  • 精神障碍增加多种躯体疾病不良临床结局风险,针对酒精使用障碍、抑郁障碍和精神分裂症的预防可减少躯体疾病患者不良结局。

主要发现

  • 72%的关联有统计学意义(p<0.05),仅2个关联达I级证据:抑郁障碍与心力衰竭患者全因死亡率(HR=1.44,95%CI:1.26-1.65)、精神分裂症与心血管疾病患者心血管死亡率(RR=1.54,95%CI:1.36-1.75)。
  • 6个关联达II级证据:抑郁障碍与糖尿病患者全因死亡率(HR=2.84,95%CI:2.00-4.03)、抑郁障碍与肾衰竭患者全因死亡率(HR=1.41,95%CI:1.31-1.51)、抑郁障碍与心肌梗死患者主要心脏事件(OR=1.52,95%CI:1.36-1.70)、抑郁障碍与糖尿病患者痴呆(HR=2.11,95%CI:1.77-2.52)、酒精使用障碍与丙肝患者失代偿性肝硬化(RR=3.15,95%CI:2.87-3.46)、精神分裂症与癌症患者癌症死亡率(SMR=1.74,95%CI:1.41-2.15)。

关键数值与推荐

  • 最大PAF为酒精使用障碍与丙肝患者失代偿性肝硬化30.56%(95%CI:27.67-33.49)。
  • 抑郁障碍与糖尿病患者全因死亡率PAF为26.81%(95%CI:16.61-37.67)。
  • 抑郁障碍与心肌梗死患者主要心脏事件PAF为13.68%(95%CI:9.87-17.58)。
  • 精神分裂症与心血管疾病患者心血管死亡率PAF为11.99%(95%CI:8.29-15.84)。
  • 抑郁障碍与肾衰竭患者全因死亡率PAF为11.59%(95%CI:9.09-14.14)。

临床怎么用

  • 对心力衰竭、糖尿病、肾衰竭、心肌梗死等躯体疾病患者应筛查并干预抑郁障碍。
  • 对心血管疾病、癌症患者应关注精神分裂症共病,以降低死亡风险。
  • 对丙肝患者应识别并干预酒精使用障碍,以预防失代偿性肝硬化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Empirical evidence indicates a significant bidirectional association between mental disorders and physical diseases, but the prospective impact of men-tal disorders on clinical outcomes of physical diseases has not been comprehensively outlined. In this PRISMA- and COSMOS-E-compliant umbrella review, we searched PubMed, PsycINFO, Embase, and Joanna Briggs Institute Database of Systematic Reviews and Implementation Reports, up to March 15, 2022, to identify systematic reviews with meta-analysis that examined the prospective association between any mental disorder and clinical outcomes of physical diseases. Primary outcomes were disease-specific mortality and all-cause mortality. Secondary outcomes were disease-specific incidence, functioning and/or disability, symptom severity, quality of life, recurrence or progression, major cardiac events, and treatment-related outcomes. Additional inclusion criteria were further applied to primary studies. Random effect models were employed, along with I2 statistic, 95% prediction intervals, small-study effects test, excess significance bias test, and risk of bias (ROBIS) assessment. Associations were classified into five credibility classes of evidence (I to IV and non-significant) according to established criteria, complemented by sensitivity and subgroup analyses to examine the robustness of the main analysis. Statistical analysis was performed using a new package for conducting umbrella reviews (https://metaumbrella.org). Population attributable fraction (PAF) and generalized impact fraction (GIF) were then calculated for class I-III associations. Forty-seven systematic reviews with meta-analysis, encompassing 251 non-overlapping primary studies and reporting 74 associations, were included (68% were at low risk of bias at the ROBIS assessment). Altogether, 43 primary outcomes (disease-specific mortality: n=17; all-cause mortality: n=26) and 31 secondary outcomes were investigated. Although 72% of associations were statistically significant (p<0.05), only two showed convincing (class I) evidence: that between depressive disorders and all-cause mortality in patients with heart failure (hazard ratio, HR=1.44, 95% CI: 1.26-1.65), and that between schizophrenia and cardiovascular mortality in patients with cardiovascular diseases (risk ratio, RR=1.54, 95% CI: 1.36-1.75). Six associations showed highly suggestive (class II) evidence: those between depressive disorders and all-cause mortality in patients with diabetes mellitus (HR=2.84, 95% CI: 2.00-4.03) and with kidney failure (HR=1.41, 95% CI: 1.31-1.51); that between depressive disorders and major cardiac events in patients with myocardial infarction (odds ratio, OR=1.52, 95% CI: 1.36-1.70); that between depressive disorders and dementia in patients with diabetes mellitus (HR=2.11, 95% CI: 1.77-2.52); that between alcohol use disorder and decompensated liver cirrhosis in patients with hepatitis C (RR=3.15, 95% CI: 2.87-3.46); and that between schizophrenia and cancer mortality in patients with cancer (standardized mean ratio, SMR=1.74, 95% CI: 1.41-2.15). Sensitivity/subgroup analyses confirmed these results. The largest PAFs were 30.56% (95% CI: 27.67-33.49) for alcohol use disorder and decompensated liver cirrhosis in patients with hepatitis C, 26.81% (95% CI: 16.61-37.67) for depressive disorders and all-cause mortality in patients with diabetes mellitus, 13.68% (95% CI: 9.87-17.58) for depressive disorders and major cardiac events in patients with myocardial infarction, 11.99% (95% CI: 8.29-15.84) for schizophrenia and cardiovascular mortality in patients with cardiovascular diseases, and 11.59% (95% CI: 9.09-14.14) for depressive disorders and all-cause mortality in patients with kidney failure. The GIFs confirmed the preventive capacity of these associations. This umbrella review demonstrates that mental disorders increase the risk of a poor clinical outcome in several physical diseases. Prevention targeting mental disorders - particularly alcohol use disorders, depressive disorders, and schizophrenia - can reduce the incidence of adverse clinical outcomes in people with physical diseases. These findings can inform clinical practice and trans-speciality preventive approaches cutting across psychiatric and somatic medicine.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Dragioti E, Radua J, Solmi M, et al. Impact of mental disorders on clinical outcomes of physical diseases: an umbrella review assessing population attributable fraction and generalized impact fraction. World Psychiatry. 2023. PMID: 36640414. doi:10.1002/wps.21068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。